Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fepixnebart in osteoarthritis
NCT04456686Phase 2Completed
- Sponsor
- Eli Lilly and Company
- Start
- Jul 2020
- Primary completion
- Apr 2021
- Modality
- Monoclonal Antibodies
- Countries
- 2
01
Overview
A Phase 2 trial of Fepixnebart in osteoarthritis (OA), sponsored by Eli Lilly and Company. Started Jul 2020; status: completed.
02
Drugs
Fepixnebart
03
Conditions
osteoarthritis (OA)
Beyond the preview
Go deeper on NCT04456686.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04456686.